MARLBOROUGH, Mass. / Sep 29, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a series of activities promoting the importance of breast cancer screenings throughout Breast Cancer Awareness Month, including a global partnership with Know Your Lemons, a nonprofit organization committed to improving early detection of breast cancer worldwide through creative and empowering education. To kick off the month, Hologic Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell on Monday, October 2, with Hologic employees as well as tennis legend and two-time breast cancer survivor Martina Navratilova.
“For the past 17 years, Hologic has rung the Nasdaq bell at the start of Breast Cancer Awareness Month to draw attention to the impact breast cancer has on our communities and to highlight the enduring need for broader awareness about the critical importance of regular screenings and early detection,” said MacMillan. “We are thrilled to be joined again at the bell ringing by tennis great Martina Navratilova, who has inspired so many as a phenomenal athlete and now as an advocate for cancer awareness and women’s health.”
This year, Hologic will also partner with Know Your Lemons, which works to improve early detection of breast cancer through symptom and screening education in a fun, accessible and inclusive way. Hologic’s partnership with the nonprofit will be a part of a broader educational campaign called #KnowBreastCancer that will leverage the creative imagery developed by Know Your Lemons founder Corrine Ellsworth-Beaumont, MFA, Ph.D. It will include dynamic posters for use in healthcare providers’ offices, sponsored content on the Know Your Lemons app explaining the importance of self-exams and custom content on both parties’ social media channels. All materials will be available in multiple languages beginning in early October.
“We’ve long admired the work done by Know Your Lemons to provide resources to women worldwide to help them understand breast health and breast cancer risk factors,” said Erik Anderson, President of Hologic’s Breast and Skeletal Health Solutions Division. “As the global leader in mammography, we know how important accessible screening education is and we’re confident this campaign with Know Your Lemons will have a meaningful impact during Breast Cancer Awareness Month and beyond.”
“As a global charity, it is critical to have the support of industry to fund our mission for early detection. Hologic’s leadership in breast health and commitment to women’s health worldwide is exemplified by their sponsoring our educational outreach, championing our message and supporting our app. We are proud to partner with such a passionate company as Hologic,” said Ellsworth-Beaumont.
Hologic and Know Your Lemons encourage the public to download the Know Your Lemons app and then share what they have learned from it on social media using #KnowBreastCancer. For more information, visit www.Hologic.com/KnowBreastCancer.
Throughout Breast Cancer Awareness Month, Hologic will reinforce the #KnowBreastCancer campaign with a series of events:
About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids, abnormal uterine bleeding and pediatric procedures.
Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Last Trade: | US$71.65 |
Daily Change: | 0.89 1.26 |
Daily Volume: | 7,640,910 |
Market Cap: | US$16.260B |
December 18, 2024 December 09, 2024 December 02, 2024 November 04, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB